Now showing items 1-1 of 1

    • OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance 

      Kuang, YH; Patel, JP; Sodani, K; Wu, CP; Liao, LQ; Patel, A; Tiwari, AK; Dai, CL; Chen, X; Fu, LW; Ambudkar, SV; Korlipara, VL; Chen, ZS (College of Biological and Physical Sciences ,Department of physics, 2012)
      OSI-930, a dual c-Kit and KDR tyrosine kinase inhibitor, is reported to have undergone a Phase I dose escalation study in patients with advanced solid tumors. A series of fifteen pyridyl and phenyl analogues of OSI-930 ...